A detailed history of Sofinnova Investments, Inc. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Sofinnova Investments, Inc. holds 1,608,540 shares of SNDX stock, worth $31 Million. This represents 2.23% of its overall portfolio holdings.

Number of Shares
1,608,540
Previous 1,075,786 49.52%
Holding current value
$31 Million
Previous $23.2 Million 64.68%
% of portfolio
2.23%
Previous 1.47%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$19.71 - $24.57 $10.5 Million - $13.1 Million
532,754 Added 49.52%
1,608,540 $38.3 Million
Q4 2023

Feb 12, 2024

SELL
$11.39 - $21.67 $5.77 Million - $11 Million
-506,505 Reduced 32.01%
1,075,786 $23.2 Million
Q2 2023

Aug 14, 2023

BUY
$19.35 - $22.31 $9.81 Million - $11.3 Million
506,867 Added 47.13%
1,582,291 $33.1 Million
Q1 2023

May 11, 2023

BUY
$20.66 - $28.98 $7.69 Million - $10.8 Million
372,350 Added 52.96%
1,075,424 $22.7 Million
Q4 2022

Feb 13, 2023

BUY
$20.64 - $26.24 $3.68 Million - $4.67 Million
178,072 Added 33.92%
703,074 $17.9 Million
Q3 2022

Nov 08, 2022

BUY
$18.51 - $24.79 $2.07 Million - $2.77 Million
111,574 Added 26.99%
525,002 $12.6 Million
Q2 2022

Aug 15, 2022

SELL
$13.64 - $19.48 $4.14 Million - $5.91 Million
-303,636 Reduced 42.34%
413,428 $7.95 Million
Q1 2022

May 16, 2022

SELL
$14.84 - $22.15 $3.47 Million - $5.19 Million
-234,162 Reduced 24.62%
717,064 $12.5 Million
Q4 2021

Feb 14, 2022

BUY
$15.23 - $22.47 $8.18 Million - $12.1 Million
537,385 Added 129.85%
951,226 $20.8 Million
Q3 2021

Nov 15, 2021

BUY
$13.87 - $19.8 $5.74 Million - $8.19 Million
413,841 New
413,841 $7.91 Million
Q2 2021

Aug 16, 2021

SELL
$13.42 - $25.18 $4.01 Million - $7.52 Million
-298,644 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$19.28 - $24.59 $1.43 Million - $1.83 Million
-74,265 Reduced 19.92%
298,644 $6.68 Million
Q4 2020

Feb 16, 2021

BUY
$15.1 - $26.44 $5.63 Million - $9.86 Million
372,909 New
372,909 $8.29 Million
Q3 2020

Nov 13, 2020

SELL
$13.39 - $17.48 $1.23 Million - $1.61 Million
-91,964 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$8.94 - $20.98 $822,158 - $1.93 Million
91,964 New
91,964 $1.36 Million
Q4 2019

Feb 14, 2020

SELL
$5.43 - $9.22 $1.32 Million - $2.24 Million
-243,150 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$7.47 - $10.76 $3,144 - $4,529
421 Added 0.17%
243,150 $1.82 Million
Q2 2019

Aug 13, 2019

BUY
$4.9 - $9.31 $143,913 - $273,434
29,370 Added 13.77%
242,729 $2.26 Million
Q1 2019

May 15, 2019

SELL
$4.26 - $6.86 $582,559 - $938,111
-136,751 Reduced 39.06%
213,359 $1.12 Million
Q4 2018

Feb 14, 2019

BUY
$3.6 - $8.42 $637,192 - $1.49 Million
176,998 Added 102.24%
350,110 $1.56 Million
Q3 2018

Nov 15, 2018

BUY
$6.33 - $8.08 $471,578 - $601,951
74,499 Added 75.55%
173,112 $1.4 Million
Q2 2018

Nov 15, 2018

BUY
$6.93 - $14.63 $597,774 - $1.26 Million
86,259 Added 698.23%
98,613 $693,000
Q2 2018

Aug 14, 2018

BUY
$6.93 - $14.63 $1,593 - $3,364
230 Added 1.9%
12,354 $87,000
Q1 2018

May 15, 2018

BUY
$8.71 - $14.82 $105,600 - $179,677
12,124 New
12,124 $173,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $1.09B
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Sofinnova Investments, Inc. Portfolio

Follow Sofinnova Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sofinnova Investments, Inc. with notifications on news.